|
Bill Would End Double Inspections of California Plants
California’s 2,000 biomedical companies face an extra layer of regulation: The state requires drug and device manufacturers to undergo an inspection by the California Food and Drug Branch in addition to federally mandated FDA inspections.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives